BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23987245)

  • 41. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
    Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK
    Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Robotic radical prostatectomy: analysis of midterm pathologic and oncologic outcomes: A historical series from a high-volume center.
    Asimakopoulos AD; Annino F; Mugnier C; Lopez L; Hoepffner JL; Gaston R; Piechaud T
    Surg Endosc; 2021 Dec; 35(12):6731-6745. PubMed ID: 33289056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy.
    Kobayashi T; Kimura T; Lee C; Inoue T; Terada N; Kono Y; Kamba T; Kim CS; Egawa S; Ogawa O
    Jpn J Clin Oncol; 2016 Aug; 46(8):762-7. PubMed ID: 27207889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years.
    Mortezavi A; Sulser T; Robbiani J; Drescher E; Disteldorf D; Eberli D; Poyet C; Baumgartner MK; Seifert HH; Hermanns T
    Clin Genitourin Cancer; 2016 Aug; 14(4):290-7. PubMed ID: 26710661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.
    Secin FP; Bianco FJ; Vickers AJ; Reuter V; Wheeler T; Fearn PA; Eastham JA; Scardino PT
    Cancer; 2006 Jun; 106(11):2369-75. PubMed ID: 16649221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.
    O'Neil LM; Walsh S; Cohen RJ; Lee S
    BJU Int; 2015 Oct; 116 Suppl 3():42-8. PubMed ID: 26218868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of the Prostate Cancer Risk Index (PRIX): a simple scoring system to predict risk of biochemical relapse after radical prostatectomy for prostate cancer.
    Yoshida T; Nakayama M; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishimura K
    Jpn J Clin Oncol; 2011 Nov; 41(11):1271-6. PubMed ID: 21971422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of positive surgical margins after radical prostatectomy at a single institution: preoperative and pathologic factors, and the impact of surgeon variability and technique on incidence and location.
    Lallas CD; Fashola Y; Den RB; Gelpi-Hammerschmidt F; Calvaresi AE; McCue P; Birbe R; Gomella LG; Trabulsi EJ
    Can J Urol; 2014 Oct; 21(5):7479-86. PubMed ID: 25347375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patients.
    Hinkelammert R; Eminaga O; Bettendorf O; Eltze E; Abbas M; Hertle L; Semjonow A
    Urol Oncol; 2014 May; 32(4):403-12. PubMed ID: 24332639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
    Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical recurrence-free conditional probability after radical prostatectomy: A dynamic prognosis.
    García-Barreras S; Sanchez-Salas R; Mejia-Monasterio C; Muttin F; Secin F; Dell'Oglio P; Nunes-Silva I; Srougi V; Barret E; Rozet F; Prapotnich D; Cathelineau X
    Int J Urol; 2019 Jul; 26(7):725-730. PubMed ID: 31001870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score.
    Pollard ME; Hobbs AR; Kwon YS; Katsigeorgis M; Lavery HJ; Levinson A; Bernstein AN; Collingwood SA; Hall SJ; Jazayeri SB; Samadi DB
    Oncol Res Treat; 2017; 40(9):508-514. PubMed ID: 28796995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Close surgical margins after radical prostatectomy mimic biochemical recurrence rates of positive margins.
    Whalen MJ; Shapiro EY; Rothberg MB; Turk AT; Woldu SL; Roy Choudhury A; Patel T; Badani KK
    Urol Oncol; 2015 Nov; 33(11):494.e9-494.e14. PubMed ID: 26259665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.